Loading company…
Emeryville-based developer of E. coli recombinant proteins using glycoproteomics for therapeutic applications.
Founded in 2008 in Emeryville, US, Redwood Bioscience develops E. coli recombinant proteins for therapeutic uses, using glycoproteomics analysis to study glycosylation and its effect on protein stability and efficacy. Its products serve drug development, bioconjugation and monoclonal antibody work for pharmaceutical, biotech and academic customers. Catalent acquired the remaining stake in the company in October 2014. The company has completed 7 deals, the most recent on October 2, 2014, and has raised USD 2.50 mn in total through a Series B round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in